Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
CRBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.64 - $61.89
Previous CloseN/A
Volume39.58K
Average Volume (3M)185.94K
Market Cap
$113.92M
Enterprise Value-$65.42M
Total Cash (Recent Filing)$132.79M
Total Debt (Recent Filing)$2.85M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 12, 2025EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding12,236,767
10 Day Avg. Volume138,883
30 Day Avg. Volume185,945
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit327.12
Enterprise Value/Ebitda1.34
Forecast
1Y Price Target
$43.14Price Target Upside363.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe FDA granted Fast Track designation for CRB-701 in relapsed/refractory metastatic cervical cancer, signaling clinical and regulatory alignment.
Clinical EfficacyCorbus reported an objective response rate of 57% among head and neck squamous cell carcinoma patients treated with CRB-701, showing promising results in its clinical trial.
Financial PositionThe company ended the quarter with $132.8 million in cash, cash equivalents, and investments, providing a strong financial position.
Bears Say
Financial PerformanceCorbus reported a net loss of $17.0 million, which was worse than the estimate.
Short InterestShort interest in Corbus Pharmaceuticals Holdings is notably high at 17.6% of the float.
Valuation ChallengesGiven the sustained multiple compression across SMID-cap biotech, the valuation framework is adjusted to reflect a more risk-averse market environment, including lowering P/E multiples and increasing discount rates.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.64 and its highest was $61.89 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $113.92M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Aug 12, 2025 which is in 8 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on May 06, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.223 by -$0.167.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.5.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,236,767 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.223. Following the earnings report the stock price went down -15.768%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.14 (363.37% Upside)
$43.14 (363.37% Upside)
Blogger Sentiment
Neutral
CRBP Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 29.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.23%
12-Months-Change
Fundamentals
Return on Equity
-44.89%
Trailing 12-Months
Asset Growth
11.28%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$43.14
▲(363.37%Upside)
Technical Analysis
Cassava Sciences
―
Atossa Therapeutics
―
Biomea Fusion
―
TScan Therapeutics
―
HilleVax, Inc
―
Ownership Overview
31.74% Insiders
8.12% Mutual Funds
1.49% Other Institutional Investors
52.39% Public Companies and
Individual Investors